TNF franchise planning

With the U.S. patent covering Enbrel etanercept set to expire in 2012, Wyeth is looking at ways to secure its anti-TNF alpha franchise beyond that date. As part of that strategy, the company's Wyeth Pharmaceuticals division was to announce on Monday this week that it has signed an exclusive research collaboration and license agreement with Ablynx N.V. to gain access to the Belgian company's nanobody platform

Read the full 669 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE